FOLH1 and xerostomia: Though [177Lu]Lu-PSMA-617 and [225Ac]Ac-PSMA were effective in cancer management [78,79,80,81], others reported dose-related xerostomia and dysphagia induced by [177Lu]Lu- and [225Ac]Ac-PSMA [82,83,84].